Granules India Limited β Q2FY27 earnings call summary
Filed 06 November 2026 Β· Official transcript
- EBITDA margin 21.6%, stable y-y; margin pressure from West Asia conflict expected to ease
- Peptide CDMO business progressing; capex underway for Vizag facility; commercial scale expected in coming quarters
- Q2 FY27 revenue grew 20% y-y to INR15,600 million; EBITDA up 21%, PAT up 39% to INR1,818 million
- Gross margin 64.4%, down 134 bps y-y due to input cost inflation; price pass-through ongoing
- 5 product launches planned in next 2 quarters, including 2 controlled substances
- Net cash position INR8,280 million; capex INR1,304 million in Q2; ROCE improved to 17.6%
- Gagillapur FDA inspection ended with 11 observations; no impact on manufacturing; response due in 15 business days
- Complex generics and controlled substances drive growth; 26 ANDAs pending approval
Open source transcript Β· View Granules India Limited research
Sign in free to track Granules India Limited and receive future summaries.